CYP2C19 Genotype-Guided Antiplatelet Therapy and 30-Day Outcomes After Percutaneous Coronary Intervention

被引：9
作者：
Williams, Alexis K. [1 ]
Klein, Melissa D. [2 ]
Martin, Jesse [1 ]
Weck, Karen E. [4 ]
Rossi, Joseph S. [2 ,3 ]
Stouffer, George A. [2 ,3 ]
Lee, Craig R. [1 ,3 ]
机构：
[1] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA
[2] Univ N Carolina, Sch Med, Div Cardiol, Chapel Hill, NC USA
[3] Univ N Carolina, McAllister Heart Inst, Chapel Hill, NC USA
[4] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA
来源：
CIRCULATION-GENOMIC AND PRECISION MEDICINE | 2019年 / 12卷 / 02期
关键词：
cardiovascular diseases; clopidogrel; pharmacogenetics; precision medicine; IMPLEMENTATION;
D O I：
10.1161/CIRCGEN.119.002441
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：97 / 99
页数：3
相关论文
共 50 条
  • [41] CYP2C19 Genotyping in Anticoagulated Patients After Percutaneous Coronary Intervention: Should It Be Routine?
    Maamari, Dimitri J.
    Jaffer, Farouc A.
    Khera, Amit, V
    Fahed, Akl C.
    CIRCULATION, 2022, 145 (10) : 721 - 723
  • [42] Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI
    Zhang, M.
    Wang, J-R
    Zhang, Y.
    Zhang, P.
    Ren, M-Y
    Jia, X-M
    Ma, L-P
    Gao, M.
    Hou, Y-L
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (20) : 10753 - 10768
  • [43] Antiplatelet Therapy and Bleeding Outcomes With CYP2C19 Genotyping
    Coons, James C. C.
    Stevenson, James M. M.
    Patel, Ami
    Smith, A. J. Conrad
    Prebehalla, Linda
    Empey, Philip E. E.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022, 27
  • [44] Genotype-Guided P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention: A Bayesian Analysis
    Parcha, Vibhu
    Heindl, Brittain F.
    Li, Peng
    Kalra, Rajat
    Limdi, Nita A.
    Pereira, Naveen L.
    Arora, Garima
    Arora, Pankaj
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2021, 14 (06): : 731 - 739
  • [45] CYP2C19genotype-guided antiplatelet therapy: promises and pitfalls
    Ellithi, Moataz
    Baye, Jordan
    Wilke, Russell A.
    PHARMACOGENOMICS, 2020, 21 (12) : 889 - 897
  • [46] Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype A POPular Genetics Subanalysis
    Claassens, Daniel M. F.
    Bergmeijer, Thomas O.
    Vos, Gerrit J. A.
    Hermanides, Renicus S.
    't Hof, Arnoud W. J. van
    van der Harst, Pim
    Barbato, Emanuele
    Morisco, Carmine
    Gin, Richard M. Tjon Joe
    Asselbergs, Folkert W.
    Mosterd, Arend
    Herrman, Jean-Paul R.
    Dewilde, Willem J. M.
    Janssen, Paul W. A.
    Kelder, Johannes C.
    Mahmoodi, Bakhtawar K.
    Deneer, Vera H. M.
    ten Berg, Jurrien M.
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2021, 14 (04) : 402 - 411
  • [47] Effects of individualized antiplatelet therapy, based on CYP2C19 genotyping, on platelet function in patients underwent percutaneous coronary intervention
    Zhang, Min
    Wang, Jiangrong
    Zhang, Yong
    Zhang, Pei
    Chao, Yangyang
    Gao, Mei
    Hou, Yinglong
    PERFUSION-UK, 2022, 37 (01): : 78 - 85
  • [48] CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis
    Jiang, Minghuan
    You, Joyce H. S.
    PHARMACOGENETICS AND GENOMICS, 2015, 25 (12) : 609 - 617
  • [49] REPLY: Precision Antiplatelet Therapy for CYP2C19 Genotype Variants for Achieving Better Clinical Outcomes
    Pereira, Naveen L.
    Rihal, Charanjit S.
    Farkouh, Michael E.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2021, 14 (13) : 1501 - 1501
  • [50] Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study
    Mathew, Roy O.
    Sidhu, Mandeep S.
    Rihal, Charanjit S.
    Lennon, Ryan
    El-Hajjar, Mohammed
    Yager, Neil
    Lyubarova, Radmila
    Abdul-Nour, Khaled
    Weitz, Steven
    O'Cochlain, D. Fearghas
    Murthy, Vishakantha
    Levisay, Justin
    Marzo, Kevin
    Graham, John
    Dzavik, Vlad
    So, Derek
    Goodman, Shaun
    Rosenberg, Yves D.
    Pereira, Naveen
    Farkouh, Michael E.
    CARDIOVASCULAR DRUGS AND THERAPY, 2024, 38 (03) : 447 - 457
12345